Larimar Therapeutics, Inc. – NASDAQ:LRMR

Add to watchlist

$3.72

-0.23

-6.06%

Market closed

Open in about 8 hours

-62.25%

month

-62.25%

quarter

-15.92%

year

Market Cap	248.52M
Enterprise value	95.79M

P/E	-3.37
EV/Sales	N/A
EV/EBITDA	-2.73
Price/Sales	N/A
Price/Book	1.05
PEG ratio	-0.06
EPS	-0.97

Revenue	N/A
EBITDA	-50.61M
Income	-45.07M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Larimar Therapeutics Stock Forecast

M Q Y

Last Year

$17

Potential upside: 356.98%

Analysts Price target
Financials & Ratios estimates

Larimar Therapeutics, Inc. (NASDAQ:LRMR): Profit margin
Jun 2023	0	-8.36M
Sep 2023	0	-9.06M
Dec 2023	0	-12.99M
Mar 2024	0	-14.65M

Larimar Therapeutics, Inc. (NASDAQ:LRMR): Debt to assets
Jun 2023	111716000	11.78M	10.55%
Sep 2023	103952000	11.24M	10.81%
Dec 2023	95935000	14.21M	14.82%
Mar 2024	248205000	17.36M	6.99%

Larimar Therapeutics, Inc. (NASDAQ:LRMR): Cash Flow
Jun 2023	-7.36M	-9.83M	0
Sep 2023	-9.2M	-46.43M	30K
Dec 2023	-9.34M	-2.62M	0
Mar 2024	-10.41M	-68.36M	162.15M

Larimar Therapeutics alternative data

Larimar Therapeutics
Employees

Larimar Therapeutics, Inc. (NASDAQ:LRMR): Employee count
Aug 2023	26
Sep 2023	26
Oct 2023	26
Nov 2023	26
Dec 2023	26
Jan 2024	26
Feb 2024	26
Mar 2024	42
Apr 2024	42
May 2024	42
Jun 2024	42
Jul 2024	42

Larimar Therapeutics
Hedge Funds Holdings Q1 2023

24.83% -75.17%

of LRMR is owned by hedge funds

29 -19

hedge funds hold LRMR stock

6.39M -32.52M

shares is hold by hedge funds

LRMR hedge funds holdings changes

Larimar Therapeutics
Insider Trading

Larimar Therapeutics, Inc. (NASDAQ:LRMR): Insider trades (number of shares)
Period	Buy	Sel
May 2023	12750	0
Dec 2023	5000	0
Feb 2024	4349825	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	16 Feb 2024	HAMILTON THOMAS EDWARD director director	Common Stock	57,208	$8.74	$499,998
Purchase	16 Feb 2024	FLYNN JAMES E director, 10 percent owner, other: * Directo.. director, 10 percent owner, oth..	Common Stock	1,430,206	$8.74	$12,500,000
Purchase	16 Feb 2024	FLYNN JAMES E director, 10 percent owner, other: * Directo.. director, 10 percent owner, oth..	Common Stock	1,430,206	$8.74	$12,500,000
Purchase	16 Feb 2024	FLYNN JAMES E director, 10 percent owner, other: * Directo.. director, 10 percent owner, oth..	Common Stock	1,430,205	$8.74	$12,499,992
Purchase	14 Feb 2024	THOMAS FRANK E director	Common Stock	2,000	$11	$22,000
Purchase	7 Dec 2023	SHANKAR GOPI officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	5,000	$3.73	$18,660
Purchase	17 May 2023	CELANO MICHAEL officer: Chief Fi..	Common Stock	5,000	$3.73	$18,630
Purchase	17 May 2023	BEN-MAIMON CAROLE director, officer..	Common Stock	5,000	$3.71	$18,525
Purchase	17 May 2023	TRUITT JOSEPH director director	Common Stock	2,750	$3.73	$10,258
Purchase	16 Sep 2022	BEN-MAIMON CAROLE director, officer..	Common Stock	31,746	$3.15	$100,000

LRMR insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS Filling date: 29 Jul 2020 Issue date: 1 Sep 2022	29 Jul 2020	1 Sep 2022
Application	Application PHARMACEUTICAL COMPOSITION COMPRISING FRATAXIN FUSION PROTEIN AND METHODS OF USE THEREOF Filling date: 13 Dec 2021 Issue date: 23 Jun 2022	13 Dec 2021	23 Jun 2022
Application	Application METHODS FOR TREATING MYELIN ASSOCIATED DISEASES AND MITOCHONDRIA ASSOCIATED DISEASES Filling date: 30 Apr 2021 Issue date: 25 Nov 2021	30 Apr 2021	25 Nov 2021
Application	Application MOLECULES FOR ORGANELLE-SPECIFIC PROTEIN DELIVERY Filling date: 26 Mar 2021 Issue date: 18 Nov 2021	26 Mar 2021	18 Nov 2021
Application	Application METHODS FOR QUANTIFYING FRATAXIN ACTIVITY Filling date: 25 Nov 2020 Issue date: 27 May 2021	25 Nov 2020	27 May 2021

Larimar Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Carole S. Ben-Maimon (1959) Chief Executive Officer, Pres & Director	66		$723,010
Mr. Michael Celano (1959) Chief Financial Officer	66		$433,980

Larimar Therapeutics
Latest News

Tuesday, 17 December 2024
13:39	What's Going On With Larimar Therapeutics Stock On Tuesday?	benzinga.com
Monday, 16 December 2024
15:21	Market 'misinterpreting' Larimar data, selloff 'overdone,' says Citi	https://thefly.com
12:17	Why Is Larimar Therapeutics Stock Trading Lower On Monday?	benzinga.com
07:00	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia	globenewswire.com
Monday, 11 November 2024
08:51	Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance	zacks.com
Friday, 8 November 2024
08:21	5 Small Drug Stocks to Buy as Trump Gets Re-Elected	zacks.com
Monday, 4 November 2024
10:55	Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet	zacks.com
Wednesday, 30 October 2024
07:00	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results	globenewswire.com
Wednesday, 16 October 2024
14:59	Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock	benzinga.com
Sunday, 6 October 2024
21:28	Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential	seekingalpha.com
Thursday, 19 September 2024
07:00	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research	globenewswire.com
Thursday, 30 May 2024
16:05	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia	globenewswire.com
Wednesday, 29 May 2024
08:45	2 Potentially High-Reward Growth Stocks to Buy Right Now	fool.com
Wednesday, 22 May 2024
12:25	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study	zacks.com
Monday, 20 May 2024
16:05	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia	globenewswire.com
Thursday, 9 May 2024
07:00	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results	globenewswire.com
Thursday, 14 March 2024
16:05	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development	globenewswire.com
Monday, 11 March 2024
16:05	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia	globenewswire.com
Wednesday, 6 March 2024
16:05	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference	GlobeNewsWire
Thursday, 31 August 2023
16:05	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference	GlobeNewsWire
Wednesday, 2 August 2023
06:02	Larimar: Friedreich's Ataxia Drug With Significant Potential	Seeking Alpha
Tuesday, 9 May 2023
13:45	Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?	Zacks Investment Research
Wednesday, 19 April 2023
09:08	New Strong Buy Stocks for April 19th	Zacks Investment Research
Wednesday, 12 April 2023
13:42	Here's Why You Should Invest in Larimar (LRMR) Stock Now	Zacks Investment Research
09:54	New Strong Buy Stocks for April 12th	Zacks Investment Research
Monday, 21 November 2022
16:05	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference	GlobeNewsWire
Thursday, 20 October 2022
12:02	5 Stocks to Bet on in an Innovation-Driven Drug Industry	Zacks Investment Research
Friday, 7 October 2022
09:02	New Strong Buy Stocks for October 7th	Zacks Investment Research
Thursday, 28 July 2022
13:16	What Makes Larimar (LRMR) a New Buy Stock	Zacks Investment Research
Thursday, 16 September 2021
08:00	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Larimar Therapeutics stock today?

One share of Larimar Therapeutics stock can currently be purchased for approximately $3.72.
When is Larimar Therapeutics's next earnings date?

Unfortunately, Larimar Therapeutics's (LRMR) next earnings date is currently unknown.
Does Larimar Therapeutics pay dividends?

No, Larimar Therapeutics does not pay dividends.
How much money does Larimar Therapeutics make?

Larimar Therapeutics has a market capitalization of 248.52M.
What is Larimar Therapeutics's stock symbol?

Larimar Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LRMR".
What is Larimar Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Larimar Therapeutics?

Shares of Larimar Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Larimar Therapeutics's key executives?
Larimar Therapeutics's management team includes the following people:
- Dr. Carole S. Ben-Maimon Chief Executive Officer, Pres & Director(age: 66, pay: $723,010)
- Mr. Michael Celano Chief Financial Officer(age: 66, pay: $433,980)
How many employees does Larimar Therapeutics have?

As Jul 2024, Larimar Therapeutics employs 42 workers.
When Larimar Therapeutics went public?

Larimar Therapeutics, Inc. is publicly traded company for more then 11 years since IPO on 19 Jun 2014.
What is Larimar Therapeutics's official website?

The official website for Larimar Therapeutics is larimartx.com.
Where are Larimar Therapeutics's headquarters?

Larimar Therapeutics is headquartered at Three Bala Plaza East, Bala Cynwyd, PA.
How can i contact Larimar Therapeutics?

Larimar Therapeutics's mailing address is Three Bala Plaza East, Bala Cynwyd, PA and company can be reached via phone at +84 45119056.
What is Larimar Therapeutics stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Larimar Therapeutics in the last 12 months, the avarage price target is $17. The average price target represents a 356.98% change from the last price of $3.72.

Larimar Therapeutics, Inc.

larimartx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

+84 45119056

Three Bala Plaza East
Bala Cynwyd, PA 19004

CIK: 0001374690
ISIN: US5171251003
CUSIP: 517125100